Clinical Trial Detail

NCT ID NCT01582204
Title Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

clear cell renal cell carcinoma

Therapies

Pazopanib

Sunitinib

Age Groups: adult

No variant requirements are available.